Brief: Otsuka Wins Japan Approval To Market Esperion’s Nexletol For Hypercholesterolemia Treatment
19/09/2025 13:31
Sept 19 (Reuters) - Esperion Therapeutics Inc ESPR.O: ESPERION PARTNER OTSUKA RECEIVES REGULATORY APPROVAL TO MARKET NEXLETOL® IN JAPAN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA ESPERION THERAPEUTICS INC - ELIGIBLE FOR SALES MILESTONES AND ROYALTIES IN JAPAN Source text: ID:nGNX1186j5 Further company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi